NeurAxis (NRXS) Q2 2026 Earnings Call Transcript

NeurAxis (NRXS) reported Q2 2026 revenue of $1.928M, up 116% YoY, with average selling price rising 28% to $992/device on a shift toward full reimbursement payers. Gross margin expanded 230 bps to 85.9%, while operating loss widened to $2.1M and net loss also $2.1M (EPS loss improved to -$0.19). Management highlighted 31% prior-authorization approval YTD vs 12% in 2025, alongside 88 ordering accounts YTD (+16%) and revenue/account averaging $40k (+68%). Cash totaled $8.3M as of June 30, 2026, with burn improved to ~$1.1M/quarter YTD but expected to tick up in 2H as revenue-growth acceleration continues, including VA ramp via 10 1099 reps.

Analysis

The setup is improving, but this is still a conversion story, not a demand story. The key market mechanism is reimbursement-driven mix shift: if payer coverage expands faster than the commercial expense base, ASP and gross margin can inflect together and the model becomes self-funding much sooner than the headline burn implies. The flip side is that this is a brittle flywheel — one payer defection, delayed Medicaid fee-schedule inclusion, or another quarter of hospital capacity constraints would slow utilization before the coverage thesis is fully visible in reported numbers.

Near term, the stock should trade on proof of sequential acceleration, not on the quarter itself. The next 1-3 months matter for whether the new sales footprint and VA reps convert into order growth; the real falsifier is if revenue per ordering account stalls despite higher SG&A, which would signal that access and workflow, not coverage, remain the bottleneck. Longer term, if management truly gets to a broad-enough covered-life threshold, the company can reduce reliance on dilutive financing and the valuation can re-rate from optionality to operating leverage.

Contrarian angle: consensus is probably over-indexing on the revenue growth rate and underappreciating how much of it is policy timing, not secular share gain. The more interesting asymmetry is that the VA channel provides a second reimbursement path with lower payer friction, but it will only matter if the company can demonstrate repeatable territory-level economics by year-end. Until then, the biggest risk is not competition; it is capital intensity outpacing visible conversion.

Key Decisions for Investors

• Long NRXS on pullbacks only, with a 1-3 month catalyst window; thesis is payer-coverage confirmation plus Q3/Q4 sequential acceleration. Falsify if sequential revenue does not inflect despite higher SG&A.
• Use a tight risk cap: exit or cut exposure if cash burn re-accelerates above roughly $1.5M/quarter without visible order conversion, because equity financing/dilution risk comes back quickly.
• Treat the VA buildout as an option value, not core earnings: add only after first evidence of territory productivity by year-end; otherwise it remains a low-visibility expense line.
• Watch for a broader re-rating trigger only if covered lives and prior-auth approval continue rising while revenue per ordering account expands again. If that metric stalls, the growth narrative is likely over-extended.